• The chronic induction of skeletal muscle AMPK activity

  2024-09-04

  

  The chronic induction of skeletal muscle AMPK activity is an attractive therapeutic approach for DMD, as it addresses multiple cellular pathways needed for powerful phenotypic plasticity, including activation of the slow oxidative myofiber program, corrective autophagic signaling, as well as regulat

• azd br Discussion Here we show opposing

  2024-09-03

  

  Discussion Here, we show opposing effects of iontophoretically administered phenylephrine,aselective α1-AR agonist, on firing of putatively DAergic and non-DAergic neurons recorded in vivo in the VTA of urethane anaesthetized rats. Phenylephrine application caused a relatively weak decrease in f

• UNC2881 br Introduction Clinical manifestations of Alzheimer

  2024-09-03

  

  Introduction Clinical manifestations of Alzheimer's disease (AD) are mainly characterized by progressive intellectual deterioration, memory impairment, cognitive impairment, and psychiatric symptoms. The pathogenesis of AD remains unclear, mainly containing genetic factors, neurotransmitter disor

• br Mechanisms of specific immunotherapy Several mechanisms m

  2024-09-03

  

  Mechanisms of specific immunotherapy Several mechanisms may be involved in specific immunotherapy of EAMG by active immunization with the therapeutic vaccine in IFA. During the therapy, the therapeutic benefits result from diversion of autoantibody specificities away from pathogenic extracellular

• Acetylcholinesterase AChE activity and expression level can

  2024-09-03

  

  Acetylcholinesterase (AChE) activity and expression level can be down regulated by TCDD in neuronal cells [3], [6]. Thus AChE could be considered as a target of the neuronal toxicity of dioxin. AChE has several types of transcripts by alternative splicing in the 3′ region of primary transcripts [7],

• An alternative to the agonist

  2024-09-03

  

  An alternative to the agonist or antagonist potential in drug discovery is the positive allosteric modulator (PAM) approach, which can augment the normal processes of neurotransmission as opposed to directly replacing or antagonizing them. PAMs are thought to bind to sites that are distinct from the

• NLX a k a F or befiradol exhibits nanomolar

  2024-09-03

  

  NLX-112 (a.k.a. F13640 or befiradol), exhibits nanomolar affinity at 5-HT1A receptors, and, in Tubastatin A HCl to the 5-HT1A receptor agonists listed above, it presents exceptional selectivity and high efficacy at these receptors (Colpaert et al., 2002, Newman-Tancredi et al., 2017). Additionally,

• br Conclusion There have been multiple clinical trials and

  2024-09-03

  

  Conclusion There have been multiple clinical trials and pre-clinical studies that have tested the utility of 5ARIs in treating prostate disease, as summarized in Fig. 1. Inhibiting androgen action through the use of finasteride and dutasteride has been established as a valuable resource for physi

• NOXA a member of the

  2024-09-03

  

  NOXA, a member of the pro-apoptotic B-cell lymphoma 2 (BCL-2) family, plays a vital role in regulating mitochondrial or inherent apoptotic pathways [7,8]. NOXA binds to MCL-1 with high affinity and interacts with A1 (known as BCL2A1), resulting in BIM release to trigger subsequent apoptosis [9]. In

• br Experimental protocols br Results and discussion br

  2024-09-03

  

  Experimental protocols Results and discussion Conclusion 15-LOX-1 is an important mammalian lipoxygenase which plays an important role in the biosynthesis of leukotrienes, lipoxins and other signalling molecules. These signalling molecules play a regulatory role in several respiratory disea

• AP activity is increased by MAP kinase stimulation in differ

  2024-09-02

  

  AP-1 activity is increased by MAP kinase stimulation in different cell types (Whitmarsh and Davis, 1996), while MKP-1, the enzyme that catalyzes the dephosphorylation and inactivation of MAP kinases in the nucleus, inhibits AP-1 (Rössler et al., 2008, Rössler and Thiel, 2009, Mayer et al., 2011, Thi

• In the largest postmortem study of autopsied individuals

  2024-09-02

  

  In the largest postmortem study of 3618 autopsied individuals, almost 75% of the individuals without Aβ pathology already harbored cortical NFT pathology mostly confined to the medial temporal regions (Murray et al., 2015). In Braak's study of 2366 autopsied individuals (Braak and Del Tredici, 2014)

• Here we provide evidence that NO contributes to changes

  2024-09-02

  

  Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa

• br Methods The study population included neuropathologically

  2024-09-02

  

  Methods The study population included 64 neuropathologically confirmed AD patients (6 male, 58 female) that were recruited into a longitudinal follow-up study of patients with dementia of Alzheimer’s type from the geriatric department of Harjula Hospital in Kuopio, Finland. At baseline the patien

• Both AD and dyslipidemias are global public health

  2024-09-02

  

  Both AD and dyslipidemias are global public health problems, and an increase in their incidence over the next decades is expected. Among many triggering elements, the increase in life expectancy is one of the main risk factors associated with the increase in the incidence of AD. Meanwhile, dyslipide

16321 records 88/1089 page Previous Next First page 上5页 8687888990 下5页 Last page